Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390400 | 1.00 | ADRB2 (0.46) | ADRB2SLC6A3SLC6A2SCN4ACYP2C9 | |
| SCHEMBL16649881 | 1.00 | ADRB2 (0.46) | ADRB2SLC6A3SLC6A2SCN4ACYP2C9 | |
| SCHEMBL390483 | 0.88 | ADRB2 (0.43) | ADRB2SLC6A3SCN4ACYP2C9MEN1 | |
| SCHEMBL1534396 | 0.82 | SLC6A4 (0.50) | ADRB2SLC6A3SLC6A2SCN4ACYP2C9 | |
| SCHEMBL1307450 | 0.82 | ADRB2 (0.50) | ADRB2SLC6A3SCN4ACYP2C9MEN1 | |
| SCHEMBL393010 | 0.82 | ADRB2 (0.50) | ADRB2SLC6A3SCN4ACYP2C9MEN1 | |
| SCHEMBL16649759 | 0.82 | SLC6A4 (0.50) | ADRB2SLC6A3SLC6A2SCN4ACYP2C9 | |
| SCHEMBL1308806 | 0.82 | ADRB2 (0.50) | ADRB2SLC6A3SCN4ACYP2C9MEN1 | |
| Hydrochloric Acid SCHEMBL1439138 | 0.80 | ADRB2 (0.48) | ADRB2SLC6A3SCN4ACYP2C9MEN1 | |
| SCHEMBL6572701 | 0.80 | TAAR1 (0.45) | SLC6A3SLC6A2CYP2C9CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118185900-B | Transaminase, preparation method and application thereof, and preparation method of amino-containing compound | 爱斯特（成都）生物制药股份有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-118185900-A | Transaminase, preparation method and application thereof, and preparation method of amino-containing compound | 爱斯特（成都）生物制药股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-109503392-A | A kind of synthetic method of (S) -3- amino -3- (4- chlorphenyl) -1- propyl alcohol | 凯瑞斯德生化(苏州)有限公司 | 2019-03-22 | — | — | CN | claimed |
| US-10080750-B2 | Aminopyrimidine derivatives for use as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | claimed |
| EP-3148998-B1 | PROCESSES FOR THE PREPARATION OF AZD5363 AND NOVEL INTERMEDIATE USED THEREIN | ASTRAZENECA AB (SE) | 2018-07-11 | — | — | EP | claimed |
| US-9879017-B2 | Processes for the preparation of AZD5363 and intermediate used therein | ASTRAZENECA AB (SE) | 2018-01-30 | — | — | US | claimed |
| US-20170217905-A1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2017-08-03 | — | — | US | claimed |
| US-20170210745-A1 | Processes for the Preparation of AZD5363 and Novel Intermediate Used Therein | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | claimed |
| EP-3148998-A1 | PROCESSES FOR THE PREPARATION OF AZD5363 AND NOVEL INTERMEDIATE USED THEREIN | Astrazeneca AB (SE) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181532-A1 | PROCESSES FOR THE PREPARATION OF AZD5363 AND NOVEL INTERMEDIATE USED THEREIN | ASTRAZENECA AB (SE) | 2015-12-03 | — | — | WO | claimed |
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | claimed |
| EP-2201012-B1 | PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2014-06-25 | — | — | EP | claimed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | claimed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | claimed |
| CN-121628876-A | Lipase mutant and preparation method and application thereof | 甘肃科聚药业有限公司 | 2026-03-10 | — | — | CN | disclosed |
| CN-121226377-A | Preparation method of carboplatin | 安礼特（上海）医药科技有限公司 | 2025-12-30 | — | — | CN | disclosed |
| CN-119684280-A | Targeting protein arginine methylation proximity-induced small molecule chimeric platform MeTAG and application thereof | 西安交通大学医学院第一附属医院 | 2025-03-25 | — | — | CN | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047563-A1 | PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10080750-B2 | Aminopyrimidine derivatives for use as modulators of kinase activity | CDK6, TK1, MAP3K19 | ADRB2 2503/4885SLC6A3 4518/4885SLC6A2 4236/4885 |
| US-20170217905-A1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF KINASE ACTIVITY | CDK6, TK1, MAP3K19 | ADRB2 2503/4885SLC6A3 4518/4885SLC6A2 4236/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | ADRB2 4117/4885SLC6A3 3929/4885SLC6A2 4598/4885 |
| US-20170210745-A1 | Processes for the Preparation of AZD5363 and Novel Intermediate Used Therein | JAK3, CDK3, STK3 | ADRB2 2734/4885SLC6A3 1537/4885SLC6A2 4623/4885 |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | ADRB2 1387/4885SLC6A3 4759/4885SLC6A2 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.